The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Synaptic scaling mediated by glial TNF-α
Stellwagen, D., & Malenka, R. C. (2006) · Nature · doi:10.1038/nature04671 · Cited by 1,715
Control of Synaptic Strength by Glial TNFα
Beattie, E. C., Stellwagen, D., Morishita, W., Bresnahan, J. C., Ha, B. K., Von Zastrow, M., Beattie, M. S., & Malenka, R. C. (2002) · Science · doi:10.1126/science.1067859 · Cited by 1,344
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“Furthermore, inhibition of p38 MAPK activation effectively blocked Ab-induced synaptic depression (Hsieh et al., 2006).”
BackgroundBlood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions
Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9025-3 · Cited by 922
Adult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Henry, C. J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M. T., Sheridan, J. F., & Godbout, J. P. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-15 · Cited by 678
Research works printed but not linked: 89
- Ashwell, 2006, The many paths to p38 mitogen-activated protein kinase activation in the immune system, Nat. Rev. Immunol., 6, 532, 10.1038/nri1865 · DOI · Paper page
- Avital, 2003, Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity, Hippocampus, 13, 826, 10.1002/hipo.10135 · DOI · Paper page
- Bains, 2007, Glia: they make your memories stick!, Trends Neurosci., 30, 417, 10.1016/j.tins.2007.06.007 · DOI
- Barbieri, 2008, Differential crosstalk between P2X7 and arachidonic acid in activation of mitogen-activated protein kinases, Neurochem. Int., 53, 255, 10.1016/j.neuint.2008.05.001 · DOI
- Barone, 2001, SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia, J. Pharmacol. Exp. Ther., 296, 312, 10.1016/S0022-3565(24)38747-6 · DOI · Paper page
- Bernardo, 2006, PPAR-gamma agonists as regulators of microglial activation and brain inflammation, Curr. Pharm. Des., 12, 93, 10.2174/138161206780574579 · DOI · Paper page
- Bhat, 1998, Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures, J. Neurosci., 18, 1633, 10.1523/JNEUROSCI.18-05-01633.1998 · DOI · Paper page
- Bhat, 2002, p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells, J. Biol. Chem., 277, 29584, 10.1074/jbc.M204994200 · DOI · Paper page
- Bodles, 2005, Secreted β-amyloid precursor protein activates microglia via JNK and p38-MAPK, Neurobiol. Aging, 26, 9, 10.1016/j.neurobiolaging.2004.02.022 · DOI
- Bogoyevitch, 2007, A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding, Drug Discov. Today, 12, 622, 10.1016/j.drudis.2007.06.008 · DOI · Paper page
- Bohac, 2002, A 24-week randomized, double-blind, placebo-controlled study of the efficacy and tolerability of TNFR: Fc (etanercept) in the treatment of dementia of the Alzheimer type, Neurobiol. Aging, 23
- Bolshakov, 2000, Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3–CA1 synapses, Nat. Neurosci., 3, 1107, 10.1038/80624 · DOI · Paper page
- Borders, 2008, The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target, BMC Neurosci., 9, S12, 10.1186/1471-2202-9-S2-S12 · DOI
- Chen, 2008, Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors, Curr. Pharm. Des., 14, 1490, 10.2174/138161208784480126 · DOI
- Chen, 2009, Identification of small-molecule inhibitors of the JIP-JNK interaction, Biochem. J., 420, 283, 10.1042/BJ20081899 · DOI
- Churcher, 2006, Tau therapeutic strategies for the treatment of Alzheimer's disease, Curr. Top. Med. Chem., 6, 579, 10.2174/156802606776743057 · DOI
- Combs, 1999, Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins, J. Neurosci., 19, 928, 10.1523/JNEUROSCI.19-03-00928.1999 · DOI · Paper page
- Culbert, 2006, MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity, J. Biol. Chem., 281, 23658, 10.1074/jbc.M513646200 · DOI · Paper page
- Da Silva, 1997, Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes, J. Biol. Chem., 272, 28373, 10.1074/jbc.272.45.28373 · DOI · Paper page
- Dambach, 2005, Potential adverse effects associated with inhibition of p38α/β MAP kinases, Curr. Top. Med. Chem., 5, 929, 10.2174/1568026054985911 · DOI
- Delgado, 2008, Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels, Glia, 56, 1091, 10.1002/glia.20681 · DOI
- Dominguez, 2005, p38 MAP kinase inhibitors: many are made, but few are chosen, Curr. Opin. Drug Discov. Devel., 8, 421
- Emsley, 2005, A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients, J. Neurol. Neurosurg. Psychiatry, 76, 1366, 10.1136/jnnp.2004.054882 · DOI · Paper page
- Giovannini, 2002, β-Amyloid induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway, Neurobiol. Dis., 11, 257, 10.1006/nbdi.2002.0538 · DOI · Paper page
- Goshen, 2007, A dual role for interleukin-1 in hippocampal-dependent memory processes, Psychoneuroendocrinology, 32, 1106, 10.1016/j.psyneuen.2007.09.004 · DOI · Paper page
- Götz, 2006, Do axonal defects in tau and APP transgenic animals model axonopathy in Alzheimer's disease?, J. Neurochem., 98, 993, 10.1111/j.1471-4159.2006.03955.x · DOI
- Götz, 2007, A decade of tau transgenic animal models and beyond, Brain Pathol., 17, 91, 10.1111/j.1750-3639.2007.00051.x · DOI · Paper page
- Griffin, 2006, Interleukin-1 mediates Alzheimer and Lewy body pathologies, J. Neuroinflammation, 3, 5, 10.1186/1742-2094-3-5 · DOI · Paper page
- Harper, 2003, MAPKs: new targets for neurodegeneration, Expert Opin. Ther. Targets, 7, 187, 10.1517/14728222.7.2.187 · DOI
- Hsieh, 2006, AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss, Neuron, 52, 831, 10.1016/j.neuron.2006.10.035 · DOI · Paper page
- Hu, 2007, Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits, Bioorg. Med. Chem. Lett., 17, 414, 10.1016/j.bmcl.2006.10.028 · DOI
- Hua, 2002, Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNFα expression in human fetal astrocytes, J. Neuroimmunol., 126, 180, 10.1016/S0165-5728(02)00055-3 · DOI
- Izumi, 2008, Long-term potentiation inhibition by low-level N-methyl-d-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase, Hippocampus, 18, 258, 10.1002/hipo.20383 · DOI
- Jana, 2008, Fibrillar amyloid-β peptides activate microglia via TLR2: implications for Alzheimer's disease, J. Immunol., 181, 7254, 10.4049/jimmunol.181.10.7254 · DOI · Paper page
- Jeohn, 2002, p38 MAP kinase is involved in lipopolysaccharide-induced dopaminergic neuronal cell death in rat mesencephalic neuron-glia cultures, Ann. N.Y. Acad. Sci., 962, 332, 10.1111/j.1749-6632.2002.tb04078.x · DOI
- Jin, 2008, Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease, J. Neuroinflammation, 5, 23, 10.1186/1742-2094-5-23 · DOI · Paper page
- Kelleher, 2007, Kinase activities increase during the development of tauopathy in htau mice, J. Neurochem., 103, 2256, 10.1111/j.1471-4159.2007.04930.x · DOI · Paper page
- Kim, 2004, Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production, Neurobiol. Aging, 25, 431, 10.1016/S0197-4580(03)00126-X · DOI · Paper page
- Lee, 1994, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis, Nature, 372, 739, 10.1038/372739a0 · DOI · Paper page
- Lee, 2000, p38 MAP kinase regulates TNF-α production in human astrocytes and microglia by multiple mechanisms, Cytokine, 12, 874, 10.1006/cyto.2000.0688 · DOI
- Legos, 2001, SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia, Brain Res., 892, 70, 10.1016/S0006-8993(00)03228-5 · DOI
- Legos, 2002, The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury, Eur. J. Pharmacol., 447, 37, 10.1016/S0014-2999(02)01890-3 · DOI
- Li, 2003, Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway, J. Neurosci., 23, 1605, 10.1523/JNEUROSCI.23-05-01605.2003 · DOI · Paper page
- Liu, 2006, Rational design of inhibitors that bind to inactive kinase conformations, Nat. Chem. Biol., 2, 358, 10.1038/nchembio799 · DOI · Paper page
- Matos, 2008, Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades, Neurosci, 156, 898, 10.1016/j.neuroscience.2008.08.022 · DOI · Paper page
- McDonald, 1998, β-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes, J. Neurosci., 18, 4451, 10.1523/JNEUROSCI.18-12-04451.1998 · DOI · Paper page
- McDonald, 1997, Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia, J. Neurosci., 17, 2284, 10.1523/JNEUROSCI.17-07-02284.1997 · DOI · Paper page
- Moult, 2008, Co-activation of p38 mitogen-activated protein kinase and protein tyrosine phosphatase underlies metabotropic glutamate receptor-dependent long-term depression, J. Physiol., 586, 2499, 10.1113/jphysiol.2008.153122 · DOI
- Moynagh, 2005, The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain, J. Anat., 207, 265, 10.1111/j.1469-7580.2005.00445.x · DOI
- Nam, 2008, 5-Chloroacetyl-2-amino-1,3-selenazoles attenuate microglial inflammatory responses through NF-κB inhibition, Eur. J. Pharmacol., 589, 53, 10.1016/j.ejphar.2008.03.034 · DOI
- Nimmrich, 2009, Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric β-amyloid, Rev. Neurosci., 20, 1, 10.1515/REVNEURO.2009.20.1.1 · DOI
- Orellana, 2007, Neuroprotective effect of TNFα against the β-amyloid neurotoxicity mediated by CDK5 kinase, Biochim. Biophys. Acta – Mol. Cell Res., 1773, 254, 10.1016/j.bbamcr.2006.10.010 · DOI
- Origlia, 2008, Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction, J. Neurosci., 28, 3521, 10.1523/JNEUROSCI.0204-08.2008 · DOI · Paper page
- Pargellis, 2002, Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site, Nat. Struct. Mol. Biol., 9, 268, 10.1038/nsb770 · DOI · Paper page
- Park, 2007, Anti-inflammatory mechanisms of isoflavone metabolites in lipopolysaccharide-stimulated microglial cells, J. Pharmacol. Exp. Ther., 320, 1237, 10.1124/jpet.106.114322 · DOI
- Parvathy, 2009, Aβ peptide conformation determines uptake and interleukin-1α expression by primary microglial cells, Neurobiol. Aging, 30, 1792, 10.1016/j.neurobiolaging.2008.01.011 · DOI
- Peifer, 2006, New approaches to the treatment of inflammatory disorders with small molecule inhibitors of p38 MAP kinase, Curr. Top. Med. Chem., 6, 113, 10.2174/156802606775270323 · DOI
- Previti, 2006, Dexamethasone diminishes the pro-inflammatory and cytotoxic effects of amyloid beta-protein in cerebrovascular smooth muscle cells, J. Neuroinflammation, 3, 18, 10.1186/1742-2094-3-18 · DOI
- Quinn, 2003, Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease, J. Neuroimmunol., 137, 32, 10.1016/S0165-5728(03)00037-7 · DOI · Paper page
- Ralay Ranaivo, 2006, Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration, J. Neurosci., 26, 662, 10.1523/JNEUROSCI.4652-05.2006 · DOI
- Rothwell, 2003, Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential, Brain Behav. Immun., 17, 152, 10.1016/S0889-1591(02)00098-3 · DOI · Paper page
- Ryu, 2004, Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus, Glia, 48, 85, 10.1002/glia.20051 · DOI
- Saha, 2007, MAPK p38 regulates transcriptional activity of NF-κB in primary human astrocytes via acetylation of p65, J. Immunol., 179, 7101, 10.4049/jimmunol.179.10.7101 · DOI · Paper page
- Scheff, 2003, Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies, Neurobiol. Aging, 24, 1029, 10.1016/j.neurobiolaging.2003.08.002 · DOI · Paper page
- Schett, 2008, The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis, Ann. Rheum. Dis., 67, 909, 10.1136/ard.2007.074278 · DOI · Paper page
- Schieven, 2005, The biology of p38 kinase: a central role in inflammation, Curr. Top. Med. Chem., 5, 921, 10.2174/1568026054985902 · DOI · Paper page
- Sheng, 2001, Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation, Neurochem. Int., 39, 341, 10.1016/S0197-0186(01)00041-9 · DOI · Paper page
- Shigematsu, 1992, Reactive microglia/macrophages phagocytose amyloid precursor protein produced by neurons following neural damage, J. Neurosci. Res., 31, 443, 10.1002/jnr.490310306 · DOI
- Simard, 2006, Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease, Neuron, 49, 489, 10.1016/j.neuron.2006.01.022 · DOI · Paper page
- Simi, 2002, The neuroprotective agents chlomethiazole and SB203580 inhibit IL-1β signalling but not its biosynthesis in rat cortical glial cells, J. Neurochem., 83, 727, 10.1046/j.1471-4159.2002.01178.x · DOI
- Sokolova, 2009, Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease, Brain Pathol., 19, 392, 10.1111/j.1750-3639.2008.00188.x · DOI · Paper page
- Sparacio, 1992, Cytokine upregulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappa B-like nuclear protein, J. Neuroimmunol., 39, 231, 10.1016/0165-5728(92)90257-L · DOI
- Srinivasan, 2004, Cell type-specific interleukin-1β signaling in the CNS, J. Neurosci., 24, 6482, 10.1523/JNEUROSCI.5712-03.2004 · DOI · Paper page
- Tanji, 2003, Interleukin-1 induces tau phosphorylation and morphological changes in cultured human astrocytes, Neuroreport, 14, 413, 10.1097/00001756-200303030-00023 · DOI
- Thalhamer, 2008, MAPKs and their relevance to arthritis and inflammation, Rheumatology, 47, 409, 10.1093/rheumatology/kem297 · DOI · Paper page
- Tobinick, 2006, TNF-aα modulation for treatment of Alzheimer's disease: a 6-month pilot study, MedGenMed, 8, 25
- Tobinick, 2008, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease, BMC Neurol., 8, 27, 10.1186/1471-2377-8-27 · DOI
- Tobinick, 2009, Perispinal etanercept for neuroinflammatory disorders, Drug Discov. Today, 14, 168, 10.1016/j.drudis.2008.10.005 · DOI
- Van Eldik, 2007, Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches, Int. Rev. Neurobiol., 82, 277, 10.1016/S0074-7742(07)82015-0 · DOI
- Volterra, 2005, Astrocytes, from brain glue to communication elements: the revolution continues, Nat. Rev. Neurosci., 6, 626, 10.1038/nrn1722 · DOI · Paper page
- White, 2005, Differential effects of oligomeric and fibrillar amyloid-β 1-42 on astrocyte-mediated inflammation, Neurobiol. Dis., 18, 459, 10.1016/j.nbd.2004.12.013 · DOI · Paper page
- Wyss-Coray, 2006, Inflammation in Alzheimer disease: driving force, bystander or beneficial response?, Nat. Med., 12, 1005
- Xiao-Dong, 2009, Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-κB and JNK signaling, Glia, 57, 1227, 10.1002/glia.20844 · DOI
- Xie, 2004, Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38, Glia, 45, 170, 10.1002/glia.10314 · DOI · Paper page
- Xing, 2008, Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt, J. Neuroinflammation, 5, 4, 10.1186/1742-2094-5-4 · DOI
- Yoshida, 2006, Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope, J. Neurochem., 99, 154, 10.1111/j.1471-4159.2006.04052.x · DOI
- Zhao, 2004, 15-Deoxy-[Delta] (12,14)-PGJ2 inhibits astrocyte IL-1 signaling: inhibition of NF-κB and MAP kinase pathways and suppression of cytokine and chemokine expression, J. Neuroimmunol., 153, 132, 10.1016/j.jneuroim.2004.05.003 · DOI
- Zhou, 2007, Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia, J. Neurochem., 102, 667, 10.1111/j.1471-4159.2007.04535.x · DOI
- Zhu, 2001, Activation of MKK6, an upstream activator of p38, in Alzheimer's disease, J. Neurochem., 79, 311, 10.1046/j.1471-4159.2001.00597.x · DOI · Paper page
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Tau protein kinases: Involvement in Alzheimer's disease
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631
Astrocyte Senescence as a Component of Alzheimer’s Disease
Bhat, R., Crowe, E. P., Bitto, A., Moh, M., Katsetos, C. D., Garcia, F. U., Johnson, F. B., Trojanowski, J. Q., Sell, C., & Torres, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045069 · Cited by 586
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Metadata
- Authors
- Munoz, L., & Ammit, A. J.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 58
- Issue
- 3
- Pages
- 561-568
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W1983816589
- Cited by
- 369
- References
- 30
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.neuropharm.2009.11.010
- The paper
- Munoz, L., & Ammit, A. J. (2010). Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2009.11.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.